US 11504426
Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist
granted A61KA61K2039/505A61K2039/545
Quick answer
US patent 11504426 (Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist) held by REGENERON PHARMACEUTICALS, INC. expires Mon Nov 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue Nov 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Nov 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 28
- CPC classes
- A61K, A61K2039/505, A61K2039/545, A61K2039/55, A61K2039/577